Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
912 PLN | -0.22% | +1.22% | -1.41% |
Mar. 23 | NEUCA S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | NEUCA S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The stock, which is currently worth 2024 to 0.34 times its sales, is clearly overvalued in comparison with peers.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.41% | 1.01B | B- | ||
+15.01% | 70.59B | C+ | ||
+2.19% | 25.06B | C+ | ||
+7.11% | 8.2B | B | ||
-20.55% | 7.96B | B- | ||
-2.98% | 7.92B | C | ||
+3.91% | 4.71B | B- | ||
+17.12% | 4.32B | B+ | ||
-1.24% | 4.01B | B- | ||
-3.44% | 3.82B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NEU Stock
- Ratings NEUCA S.A.